[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 31 of about 31
1. Haddow LJ, Davies S, Buckingham S, Miller RF: Kaposi's sarcoma infiltrating skeletal muscle. Sex Transm Infect; 2002 Dec;78(6):464-5
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Kaposi's sarcoma infiltrating skeletal muscle.
  • An HIV-1 antibody positive black African man with plasma cell variant Castleman's disease and cutaneous Kaposi's sarcoma, despite receiving chemotherapy, had progressive disease.
  • In addition, he developed pain and swelling behind the right knee.
  • Histology of an ultrasound guided biopsy showed Kaposi's sarcoma infiltrating the head of gastrocnemius.
  • [MeSH-major] Muscle Neoplasms / pathology. Muscle, Skeletal / pathology. Sarcoma, Kaposi / pathology. Skin Neoplasms / pathology
  • [MeSH-minor] Adult. Giant Lymph Node Hyperplasia / complications. HIV Infections / complications. Humans. Knee. Male. Neoplasm Invasiveness

  • MedlinePlus Health Information. consumer health - Kaposi's Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12473815.001).
  • [ISSN] 1368-4973
  • [Journal-full-title] Sexually transmitted infections
  • [ISO-abbreviation] Sex Transm Infect
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC1758342
  •  go-up   go-down


2. Apoola A, Ross J, Duddy MJ, Mudaliar V, Jones EL, Huengsberg M, Miller RF: Central pontine myelinolysis complicating treatment of multicentric Castleman's disease and Kaposi's sarcoma in a patient with AIDS. Sex Transm Infect; 2003 Jun;79(3):179-84
MedlinePlus Health Information. consumer health - Kaposi's Sarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Central pontine myelinolysis complicating treatment of multicentric Castleman's disease and Kaposi's sarcoma in a patient with AIDS.
  • Lymph node biopsy showed both Kaposi's sarcoma and multicentric Castleman's disease.
  • Despite antiretroviral therapy and chemotherapy the patient deteriorated, developing confusion and dysphasia.
  • Despite supportive therapy the patient died.
  • [MeSH-major] AIDS-Related Complex / diagnosis. Giant Lymph Node Hyperplasia / diagnosis. Myelinolysis, Central Pontine / diagnosis. Sarcoma, Kaposi / diagnosis
  • [MeSH-minor] Adult. Fatal Outcome. Female. Humans. Magnetic Resonance Imaging. Tomography, X-Ray Computed


3. Loi S, Goldstein D, Clezy K, Milliken ST, Hoy J, Chipman M: Castleman's disease and HIV infection in Australia. HIV Med; 2004 May;5(3):157-62
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PATIENTS AND METHODS: HIV-infected patients diagnosed with MCD since 1994, were identified from three major HIV treatment centres in Australia.
  • All but one patient was receiving HAART at the time of diagnosis.
  • Nine of the 11 patients had Kaposi's sarcoma (KS) and two patients also developed non-Hodgkin's Lymphoma (NHL).
  • All patients received chemotherapy for MCD.
  • The response rate from Chemotherapy was 64%.
  • CONCLUSION: MCD in HIV infected patients is a rare and life-threatening disorder.
  • There is limited recent information on optimal treatment for MCD.
  • In our experience, treatment with liposomal anthracycline was associated with good response rates and acceptable toxicity in several patients, and therefore merits further exploration to establish its role.
  • Treatment in the future may concentrate on novel agents such as anti-interleukin 6, anti-CD20 antibodies, thalidomide and viral ablation.
  • [MeSH-major] Giant Lymph Node Hyperplasia / virology. HIV Infections / complications
  • [MeSH-minor] Adult. Alkylating Agents / therapeutic use. Antiretroviral Therapy, Highly Active. Follow-Up Studies. Humans. Male. Middle Aged. Prognosis. Retrospective Studies. Victoria / epidemiology

  • Genetic Alliance. consumer health - Castleman's Disease.
  • Genetic Alliance. consumer health - HIV.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15139981.001).
  • [ISSN] 1464-2662
  • [Journal-full-title] HIV medicine
  • [ISO-abbreviation] HIV Med.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Alkylating Agents
  •  go-up   go-down


Advertisement
4. Rivero Fernández M, García Martos M, Sanz Moya P, Vázquez Romero M, Fernández Amago MT, García Benayas MT, Sánchez-Pobre Bejarano P: [Kaposi's sarcoma with colorectal and anal canal involvement]. Gastroenterol Hepatol; 2010 Aug-Sep;33(7):508-11
MedlinePlus Health Information. consumer health - Kaposi's Sarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Kaposi's sarcoma with colorectal and anal canal involvement].
  • [Transliterated title] Sarcoma de Kaposi con afectación colorrectal y del canal anal.
  • Kaposi's sarcoma (KS) is a low-grade vascular tumor, with four main variants, one of which is fairly prevalent in HIV-infected patients.
  • Mucocutaneus and lymph node involvement is characteristic.
  • The patient was treated with highly active antiretroviral therapy and systemic chemotherapy, with partial response.
  • Local radiation therapy of the rectum produced local remission.
  • [MeSH-major] Anus Neoplasms. Colorectal Neoplasms. Neoplasms, Multiple Primary. Sarcoma, Kaposi

  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] .
  • (PMID = 20630624.001).
  • [ISSN] 0210-5705
  • [Journal-full-title] Gastroenterología y hepatología
  • [ISO-abbreviation] Gastroenterol Hepatol
  • [Language] spa
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Spain
  •  go-up   go-down


5. Cazorla Jiménez A, Górgolas Hernández-Mora M, Fernández Guerrero M, Renedo Pascual G, Rivas Manga C: [Multicenter Castleman disease in AIDS. Its relationship with HHV-8 or herpes virus associated to Kaposi's sarcoma. Study of two cases]. Rev Clin Esp; 2005 Dec;205(12):607-9
HIV InSite. treatment guidelines - Human Herpesvirus-8 .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Multicenter Castleman disease in AIDS. Its relationship with HHV-8 or herpes virus associated to Kaposi's sarcoma. Study of two cases].
  • [Transliterated title] Enfermedad de Castleman multicéntrica en sida. Su relación con el VHH-8 o virus herpes asociado al sarcoma de Kaposi. Estudio de dos casos.
  • Two cases of Castleman disease multicenter in HIV positive patients with Kaposi's sarcoma are presented.
  • Both patients have multiple adenopathies, hepatomegaly and symptoms B on diagnosis.
  • One of them had a favorable response to chemotherapy treatment and another died.
  • [MeSH-major] Acquired Immunodeficiency Syndrome / complications. Giant Lymph Node Hyperplasia / complications. Herpesvirus 8, Human. Sarcoma, Kaposi / complications

  • Genetic Alliance. consumer health - AIDS-HIV.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • MedlinePlus Health Information. consumer health - Kaposi's Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16527182.001).
  • [ISSN] 0014-2565
  • [Journal-full-title] Revista clínica española
  • [ISO-abbreviation] Rev Clin Esp
  • [Language] spa
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Spain
  •  go-up   go-down


6. Gérard L, Bérezné A, Galicier L, Meignin V, Obadia M, De Castro N, Jacomet C, Verdon R, Madelaine-Chambrin I, Boulanger E, Chevret S, Agbalika F, Oksenhendler E: Prospective study of rituximab in chemotherapy-dependent human immunodeficiency virus associated multicentric Castleman's disease: ANRS 117 CastlemaB Trial. J Clin Oncol; 2007 Aug 1;25(22):3350-6
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prospective study of rituximab in chemotherapy-dependent human immunodeficiency virus associated multicentric Castleman's disease: ANRS 117 CastlemaB Trial.
  • PURPOSE: Single-agent chemotherapy is usually effective in HIV-associated multicentric Castleman's disease (MCD).
  • However, in most patients, chemotherapy cannot be discontinued.
  • PATIENTS AND METHODS: To evaluate the efficacy of four weekly rituximab infusions (375 mg/m(2)) after discontinuation of chemotherapy in HIV-associated MCD, 24 patients were enrolled onto a prospective open-label trial.
  • RESULTS: At study entry, the median time from MCD diagnosis was 21 months.
  • All patients had stable disease on chemotherapy and were dependent on chemotherapy for a median time of 13 months.
  • Sustained remission (SR) off treatment at day 60 (primary end point) was achieved in 22 patients (92%).
  • Seventeen patients (71%) were alive in SR at day 365 without specific treatment, and the overall survival rate was 92% (95% CI, 71% to 98%).
  • Mild exacerbation of Kaposi's sarcoma (KS) lesions was observed in eight of 12 patients with previous KS.
  • CONCLUSION: Rituximab was both effective and safe in HIV-infected patients with chemotherapy-dependent MCD.
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Giant Lymph Node Hyperplasia / complications. Giant Lymph Node Hyperplasia / drug therapy. HIV Infections / complications
  • [MeSH-minor] Adult. Aged. Antibodies, Monoclonal, Murine-Derived. Female. Humans. Infusions, Intravenous. Male. Middle Aged. Polymerase Chain Reaction. Prospective Studies. Rituximab. Survival Analysis. Treatment Outcome

  • Genetic Alliance. consumer health - Castleman's Disease.
  • Genetic Alliance. consumer health - Multicentric Castleman's Disease.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • MedlinePlus Health Information. consumer health - HIV/AIDS in Women.
  • Hazardous Substances Data Bank. RITUXIMAB .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17664482.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 4F4X42SYQ6 / Rituximab
  •  go-up   go-down


7. Inoubli S, Toutous-Trellu L, Cathomas G, Oksenhendler E, Hirschel B, El Amari EB: Human herpes virus 8 replication during disseminated tuberculosis in a man with human immunodeficiency virus: a case report. J Med Case Rep; 2009;3:113

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • INTRODUCTION: Human herpes virus 8 (HHV-8) is mainly responsible for the development of Kaposi's sarcoma and multicentric Castleman's disease in immunocompromised patients with untreated human immunodeficiency virus.
  • Positive viral loads have been described in cases of Kaposi's sarcoma and multicentric Castleman's disease, with higher values found in the latter.
  • We describe the case of a patient with HIV in whom a high level of HHV-8 replication was detected and who contracted an opportunistic disease other than multicentric Castleman's disease or Kaposi's sarcoma.
  • Our first presumptive diagnosis was disseminated tuberculosis.
  • However, since the cultures (sputum, bronchoalveolar lavage, blood, urine and lymph node biopsies) for mycobacteria were negative, the diagnosis was expanded to include multicentric Castleman's disease which was supported by high HHV-8 viral loads in the patient's blood: 196,000 copies/ml in whole blood, 39,400 copies/ml in plasma and 260 copies/10E5 in peripheral blood mononuclear cells.
  • However, the histology and positive polymerase chain reaction assay for Mycobacterium tuberculosis complex of a second lymph node biopsy enabled us to conclude that the patient had disseminated tuberculosis and we started the patient on antituberculosis treatment.
  • The initial analysis was nullified by the diagnosis of a disease that was unrelated to HHV-8.
  • The diagnosis of multicentric Castleman's disease needs to be studied further to determine its sensitivity and specificity.
  • Finally, when faced with the dilemma of urgently starting chemotherapy on a patient whose condition is deteriorating and whose clinical presentation suggests multicentric Castleman's disease, high HHV-8 viral loads should be interpreted with caution and histological analysis of lymph nodes or liver biopsies should be obtained first.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Curr Opin Hematol. 2007 Jul;14(4):354-9 [17534161.001]
  • [Cites] Transplantation. 2007 Feb 27;83(4):433-8 [17318076.001]
  • [Cites] J Clin Microbiol. 2006 Nov;44(11):3863-71 [16943357.001]
  • [Cites] Int J STD AIDS. 2006 Jan;17(1):19-24; quiz 25 [16409673.001]
  • [Cites] J Med Virol. 2005 Aug;76(4):541-6 [15977227.001]
  • [Cites] J Infect Dis. 1998 Dec;178(6):1791-4 [9815236.001]
  • [Cites] AIDS. 2000 Jan 7;14(1):98-9 [10714578.001]
  • [Cites] Clin Infect Dis. 2002 Oct 1;35(7):880-2 [12228826.001]
  • [Cites] J Med Virol. 2002 Nov;68(3):399-403 [12226828.001]
  • [Cites] AIDS. 2000 Sep 29;14(14):2109-16 [11061651.001]
  • [Cites] Blood. 2000 Sep 15;96(6):2069-73 [10979949.001]
  • [Cites] Am J Pathol. 2000 Jun;156(6):1961-71 [10854219.001]
  • [Cites] AIDS. 1996 Jan;10(1):61-7 [8924253.001]
  • (PMID = 19946591.001).
  • [ISSN] 1752-1947
  • [Journal-full-title] Journal of medical case reports
  • [ISO-abbreviation] J Med Case Rep
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2783054
  •  go-up   go-down


8. Pérez CL, Rudoy S: Anti-CD20 monoclonal antibody treatment of human herpesvirus 8-associated, body cavity-based lymphoma with an unusual phenotype in a human immunodeficiency virus-negative patient. Clin Diagn Lab Immunol; 2001 Sep;8(5):993-6
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Anti-CD20 monoclonal antibody treatment of human herpesvirus 8-associated, body cavity-based lymphoma with an unusual phenotype in a human immunodeficiency virus-negative patient.
  • Human herpesvirus 8 (HHV-8), or Kaposi's sarcoma-associated herpesvirus, is a gammaherpesvirus first detected in Kaposi's sarcoma tumor cells and subsequently in primary effusion lymphoma (PEL) tumor cells and peripheral blood mononuclear cells from PEL patients.
  • PCR performed on a lymph node specimen and in liquid effusion was positive for HHV-8 and negative for Epstein-Barr virus.
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Antigens, CD20 / immunology. HIV Seronegativity / immunology. Herpesviridae Infections / complications. Herpesviridae Infections / drug therapy. Herpesvirus 8, Human. Lymphoma, B-Cell / drug therapy. Lymphoma, B-Cell / etiology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Lancet. 1995 Apr 22;345(8956):1043-4 [7723505.001]
  • [Cites] N Engl J Med. 1995 May 4;332(18):1186-91 [7700311.001]
  • [Cites] N Engl J Med. 1995 Oct 5;333(14):943 [7666892.001]
  • [Cites] Blood. 1995 Oct 1;86(7):2708-14 [7670109.001]
  • [Cites] Blood. 1996 Jun 15;87(12):4937-43 [8652805.001]
  • [Cites] Am J Pathol. 1996 Jul;149(1):53-7 [8686762.001]
  • [Cites] Blood. 1996 Jul 15;88(2):645-56 [8695812.001]
  • [Cites] Br J Haematol. 1996 Sep;94(3):533-43 [8790156.001]
  • [Cites] Blood. 1996 Oct 15;88(8):3124-8 [8874212.001]
  • [Cites] J Virol Methods. 1997 Feb;64(1):19-26 [9029526.001]
  • [Cites] Radiology. 1997 Nov;205(2):459-63 [9356629.001]
  • [Cites] Med Clin (Barc). 1997 Nov 22;109(18):712-4 [9499149.001]
  • [Cites] Blood. 1998 Mar 1;91(5):1671-9 [9473233.001]
  • [Cites] Leuk Lymphoma. 1998 Jan;28(3-4):255-64 [9517497.001]
  • [Cites] Blood. 1998 Apr 1;91(7):2475-81 [9516148.001]
  • [Cites] N Engl J Med. 1998 Aug 13;339(7):444-9 [9700178.001]
  • [Cites] J Clin Oncol. 1998 Aug;16(8):2825-33 [9704735.001]
  • [Cites] Am J Pathol. 1998 Nov;153(5):1609-14 [9811353.001]
  • [Cites] Leukemia. 1998 Nov;12(11):1806-9 [9823957.001]
  • [Cites] Oncology (Williston Park). 1998 Oct;12(10 Suppl 8):63-76 [9830635.001]
  • [Cites] Lab Invest. 1998 Dec;78(12):1637-42 [9881964.001]
  • [Cites] Leukemia. 1999 May;13(5):664-70 [10374868.001]
  • [Cites] J Clin Oncol. 1999 Jan;17(1):268-76 [10458242.001]
  • [Cites] Eur Respir J. 1999 Nov;14(5):1231-4 [10596717.001]
  • [Cites] Arch Pathol Lab Med. 2000 May;124(5):753-5 [10782162.001]
  • [Cites] Scand J Immunol. 2000 Jun;51(6):634-41 [10849376.001]
  • [Cites] Am J Hematol. 2000 Aug;64(4):317-8 [10911388.001]
  • [Cites] Cancer. 1979 Feb;43(2):417-25 [84706.001]
  • [Cites] Blood. 1989 Feb 15;73(3):792-9 [2537119.001]
  • [Cites] J Exp Med. 1989 Jun 1;169(6):2191-8 [2543732.001]
  • [Cites] Am J Clin Pathol. 1990 Aug;94(2):170-5 [2371971.001]
  • [Cites] Blood. 1994 Sep 1;84(5):1361-92 [8068936.001]
  • [Cites] Blood. 1994 Oct 15;84(8):2457-66 [7522629.001]
  • [Cites] Science. 1994 Dec 16;266(5192):1865-9 [7997879.001]
  • [Cites] Mod Pathol. 1995 Jan;8(1):39-45 [7731940.001]
  • (PMID = 11527816.001).
  • [ISSN] 1071-412X
  • [Journal-full-title] Clinical and diagnostic laboratory immunology
  • [ISO-abbreviation] Clin. Diagn. Lab. Immunol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antigens, CD20
  • [Other-IDs] NLM/ PMC96184
  •  go-up   go-down


9. Duman S, Töz H, Aşçi G, Alper S, Ozkahya M, Unal I, Celik A, Ok E, Başçi A: Successful treatment of post-transplant Kaposi's sarcoma by reduction of immunosuppression. Nephrol Dial Transplant; 2002 May;17(5):892-6
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Successful treatment of post-transplant Kaposi's sarcoma by reduction of immunosuppression.
  • BACKGROUND: The aim of this study was to investigate retrospectively the clinical presentation, the efficacy of reducing immunosuppression and the consequences of this therapeutic approach in Kaposi's sarcoma (KS) developing after renal transplantation.
  • All were on prednisone, azathioprine (AZT) and cylcosporin treatment.
  • Typical Kaposi's lesions were present in the skin of 11 out of l2 patients.
  • In the only patient without skin involvement, who died from haemophagocytic histiocytic syndrome caused by septicaemia, KS was diagnosed post-mortem in a lymph node.
  • In five patients only skin involvement was present, while the others also had visceral involvement (oropharynx in two patients, trachea and lung in three, lymph node in two, stomach and duodenum in two).
  • Cyclosporin was stopped within 1 month after KS diagnosis, and AZT was stopped in three patients.
  • Reduction or discontinuation of immunosuppression caused complete remission in all patients without surgical intervention, chemotherapy or radiotherapy.
  • [MeSH-major] Immunosuppressive Agents / administration & dosage. Kidney Transplantation / adverse effects. Sarcoma, Kaposi / etiology. Sarcoma, Kaposi / therapy. Skin Neoplasms / etiology. Skin Neoplasms / therapy
  • [MeSH-minor] Adult. Dose-Response Relationship, Drug. Drug Administration Schedule. Female. Humans. Male. Middle Aged. Retrospective Studies

  • MedlinePlus Health Information. consumer health - Kaposi's Sarcoma.
  • MedlinePlus Health Information. consumer health - Kidney Transplantation.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11981080.001).
  • [ISSN] 0931-0509
  • [Journal-full-title] Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association
  • [ISO-abbreviation] Nephrol. Dial. Transplant.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Immunosuppressive Agents
  •  go-up   go-down


10. Pastor MA, Vasco B, Mosquera JM, Debén G, Bautista P, Requena L: [Two HHV8-related illnesses in a HIV-negative patient: Kaposi's sarcoma and multicentric Castleman's disease. Response to treatment with Rituximab and CHOP]. Actas Dermosifiliogr; 2006 Jul-Aug;97(6):385-90
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Two HHV8-related illnesses in a HIV-negative patient: Kaposi's sarcoma and multicentric Castleman's disease. Response to treatment with Rituximab and CHOP].
  • [Transliterated title] Dos enfermedades relacionadas con el VHH-8 en un paciente VIH-negativo: sarcoma de Kaposi y enfermedad de Castleman multicéntrica. Respuesta a tratamiento con rituximab y CHOP.
  • Human herpes virus 8 (HHV8) was discovered in 1994 in the biopsy of a Kaposi's sarcoma in a patient with AIDS.
  • Since then it has been identified in all variants of Kaposi's sarcoma and in another two rare disorders: multicentric Castleman's disease and primary body-cavity based lymphomas.
  • The case discusses a 68 year old, HIV-negative male patient, presenting Kaposi's sarcoma for one year and being monitored by dermatology, who presented for weakness, anorexia and fever.
  • On examination, he was found to have adenitis of the lymph nodes in his neck, underarm and groin.
  • Patient received 8 cycles of CHOP and rituximab, leading to complete disappearance of the adenitis and general symptoms, with no worsening of his Kaposi's sarcoma.
  • Patient remained in complete remission for 10 months after treatment.
  • This paper discusses the case of a HIV-, HHV8+ patient, diagnosed with classic Kaposi's sarcoma, who developed multicentric plasma cell variant Castleman's disease.
  • Treatment with rituximab combined with CHOP chemotherapy was effective in this case, and no worsening of the patient's KS was observed.
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Antineoplastic Agents / therapeutic use. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Giant Lymph Node Hyperplasia / complications. HIV Seronegativity. Herpesvirus 8, Human. Sarcoma, Kaposi / complications. Sarcoma, Kaposi / drug therapy. Skin Neoplasms / complications. Skin Neoplasms / drug therapy
  • [MeSH-minor] Aged. Antibodies, Monoclonal, Murine-Derived. Cyclophosphamide / therapeutic use. Doxorubicin / therapeutic use. Humans. Male. Prednisone / therapeutic use. Rituximab. Vincristine / therapeutic use


11. Berber I, Altaca G, Aydin C, Dural A, Kara VM, Yigit B, Turkmen A, Titiz MI: Kaposi's sarcoma in renal transplant patients: predisposing factors and prognosis. Transplant Proc; 2005 Mar;37(2):967-8
MedlinePlus Health Information. consumer health - Kidney Transplantation.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Kaposi's sarcoma in renal transplant patients: predisposing factors and prognosis.
  • Among 772 kidney transplant recipients in two centers 25 patients developed Kaposi's sarcoma (KS) (3.2%).
  • All patients had mucocutaneous involvement, which was multiple in 54.5%.
  • Visceral involvement, and lymph node involvement, or both was detected in seven patients.
  • First-line treatment was to stop CsA and reduce the doses of the other drugs.
  • Fourteen (63.6%) patients experienced complete remissions, including six who required additional chemotherapy or radiotherapy after incomplete or lack of responses to first-line treatment.
  • Seven patients returned to hemodialysis at a mean of 36 months after the diagnosis of KS.
  • Chemotherapy or radiotherapy should be initiated for patients with multiple, diffuse, and rapidly progressive lesions or organ dysfunction in addition to withdrawal of CsA and tapering of other drugs.
  • [MeSH-major] Kidney Transplantation / pathology. Postoperative Complications / epidemiology. Sarcoma, Kaposi / epidemiology
  • [MeSH-minor] Adolescent. Adult. Aged. Antilymphocyte Serum / therapeutic use. Female. Follow-Up Studies. Graft Rejection / drug therapy. Graft Rejection / epidemiology. Humans. Immunosuppressive Agents / therapeutic use. Male. Medical Records. Middle Aged. Prognosis. Retrospective Studies. Time Factors

  • MedlinePlus Health Information. consumer health - After Surgery.
  • MedlinePlus Health Information. consumer health - Kaposi's Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15848593.001).
  • [ISSN] 0041-1345
  • [Journal-full-title] Transplantation proceedings
  • [ISO-abbreviation] Transplant. Proc.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antilymphocyte Serum; 0 / Immunosuppressive Agents
  •  go-up   go-down


12. Senanayake S, Kelly J, Lloyd A, Waliuzzaman Z, Goldstein D, Rawlinson W: Multicentric Castleman's disease treated with antivirals and immunosuppressants. J Med Virol; 2003 Nov;71(3):399-403
Hazardous Substances Data Bank. PREDNISOLONE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A patient negative for human immunodeficiency virus (HIV) developed multicentric Castleman's disease (MCD) and Kaposi's sarcoma (KS) associated with active human herpesvirus 8 (HHV-8) infection.
  • He was treated with sequential antiviral therapy, chemotherapy, and corticosteroids.
  • No consistent change in HHV-8 levels was found with antiviral therapy.
  • We demonstrate that in this patient antiviral therapy was clinically ineffective, and did not alter HHV-8 levels, but that corticosteroid and combination chemotherapy led to clinical improvement.
  • [MeSH-major] Antiviral Agents / therapeutic use. Cytosine / analogs & derivatives. Cytosine / therapeutic use. Foscarnet / therapeutic use. Giant Lymph Node Hyperplasia / drug therapy. Immunosuppressive Agents / therapeutic use. Organophosphonates. Organophosphorus Compounds / therapeutic use
  • [MeSH-minor] Aged. Anti-Inflammatory Agents / administration & dosage. Anti-Inflammatory Agents / therapeutic use. Antineoplastic Agents, Alkylating / administration & dosage. Antineoplastic Agents, Alkylating / therapeutic use. Chlorambucil / administration & dosage. Chlorambucil / therapeutic use. Drug Therapy, Combination. Herpesvirus 8, Human / genetics. Herpesvirus 8, Human / isolation & purification. Herpesvirus 8, Human / physiology. Humans. Male. Prednisolone / administration & dosage. Prednisolone / therapeutic use. Sarcoma, Kaposi / drug therapy. Sarcoma, Kaposi / virology. Treatment Outcome

  • Genetic Alliance. consumer health - Castleman's Disease.
  • Genetic Alliance. consumer health - Multicentric Castleman's Disease.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CIDOFOVIR .
  • Hazardous Substances Data Bank. CHLORAMBUCIL .
  • Hazardous Substances Data Bank. Foscarnet .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2003 Wiley-Liss, Inc.
  • (PMID = 12966545.001).
  • [ISSN] 0146-6615
  • [Journal-full-title] Journal of medical virology
  • [ISO-abbreviation] J. Med. Virol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anti-Inflammatory Agents; 0 / Antineoplastic Agents, Alkylating; 0 / Antiviral Agents; 0 / Immunosuppressive Agents; 0 / Organophosphonates; 0 / Organophosphorus Compounds; 18D0SL7309 / Chlorambucil; 364P9RVW4X / Foscarnet; 8J337D1HZY / Cytosine; 9PHQ9Y1OLM / Prednisolone; JIL713Q00N / cidofovir
  •  go-up   go-down


13. Aoki Y, Tosato G: Targeted inhibition of angiogenic factors in AIDS-related disorders. Curr Drug Targets Infect Disord; 2003 Jun;3(2):115-28
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Despite its dramatic decrease in frequency after the introduction of highly active antiretroviral therapy (HAART), Kaposi's sarcoma (KS) remains the most common neoplastic manifestation of AIDS.
  • Viral products from the recently described Kaposi's sarcoma-associated herpesvirus (KSHV) also exhibit potent angiogenic activities.
  • In this review, we summarize current knowledge and hypothesis regarding the cellular and viral angiogenic factors involved in the pathogeneses of AIDS-related malignancies, and discuss novel therapeutic strategies based on targeting pro-angiogenic factors.
  • [MeSH-major] Acquired Immunodeficiency Syndrome / complications. Angiogenesis Inhibitors / pharmacology. Endothelial Growth Factors / antagonists & inhibitors. Fibroblast Growth Factor 2 / antagonists & inhibitors. Neovascularization, Pathologic / therapy. Sarcoma, Kaposi / blood supply. Sarcoma, Kaposi / therapy
  • [MeSH-minor] Giant Lymph Node Hyperplasia / complications. Giant Lymph Node Hyperplasia / pathology. Herpesviridae Infections / complications. Herpesviridae Infections / pathology. Herpesvirus 8, Human / growth & development. Humans. Lymphoma, AIDS-Related / complications. Lymphoma, AIDS-Related / pathology. Vascular Endothelial Growth Factor A

  • Genetic Alliance. consumer health - AIDS-HIV.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • MedlinePlus Health Information. consumer health - Kaposi's Sarcoma.
  • COS Scholar Universe. author profiles.
  • HIV InSite. treatment guidelines - Human Herpesvirus-8 .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12769789.001).
  • [ISSN] 1568-0053
  • [Journal-full-title] Current drug targets. Infectious disorders
  • [ISO-abbreviation] Curr Drug Targets Infect Disord
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Angiogenesis Inhibitors; 0 / Endothelial Growth Factors; 0 / Vascular Endothelial Growth Factor A; 103107-01-3 / Fibroblast Growth Factor 2
  • [Number-of-references] 163
  •  go-up   go-down


14. Kenyon C, Pillay K, Jacobs P: Castleman's disease and retroviral therapy. Transfus Apher Sci; 2007 Aug;37(1):81-4
HIV InSite. treatment guidelines - Human Herpesvirus-8 .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Castleman's disease and retroviral therapy.
  • The escalating pandemic of the acquired immunodeficiency disease in sub-Saharan Africa is associated with an increasing incidence of the lymphoproliferative disorders where evidence shows that highly active retroviral therapy can reconstitute immunologic competence and, at least in some groups exemplified by Kaposi's sarcoma, result in an outcome comparable to uninfected controls.
  • Paradoxically other subtypes are less responsive exemplified by Burkitt lymphoma and multicentric Castleman's disease, where they are localised and may present after starting treatment.
  • This association provides a model to test the concept that pathogenesis may reflect an aberrant response to antigens including human herpesvirus-8 thereby renewing focus on proactive inclusion of anti-herpes drugs with conventional treatment for retrovirus particularly prior to initiating chemotherapy.
  • [MeSH-major] Acquired Immunodeficiency Syndrome / complications. Giant Lymph Node Hyperplasia / etiology
  • [MeSH-minor] Adult. Africa South of the Sahara. Burkitt Lymphoma / epidemiology. Burkitt Lymphoma / etiology. Burkitt Lymphoma / pathology. Fatal Outcome. Female. Herpesvirus 8, Human. Humans. Models, Biological. Reverse Transcriptase Inhibitors / administration & dosage. Sarcoma, Kaposi / epidemiology. Sarcoma, Kaposi / etiology. Sarcoma, Kaposi / pathology. Tuberculosis, Pulmonary / complications. Tuberculosis, Pulmonary / drug therapy. Tuberculosis, Pulmonary / epidemiology. Tuberculosis, Pulmonary / pathology

  • Genetic Alliance. consumer health - Castleman's Disease.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17931977.001).
  • [ISSN] 1473-0502
  • [Journal-full-title] Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis
  • [ISO-abbreviation] Transfus. Apher. Sci.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Reverse Transcriptase Inhibitors
  •  go-up   go-down


15. Puxeddu R, Parodo G, Locci F, Puxeddu I, Manconi PE, Ferreli C: Parotid mass as an early sign of Kaposi's sarcoma associated with human herpesvirus 8 infection. J Laryngol Otol; 2002 Jun;116(6):470-3
MedlinePlus Health Information. consumer health - Kaposi's Sarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Parotid mass as an early sign of Kaposi's sarcoma associated with human herpesvirus 8 infection.
  • Kaposi's sarcoma of an intraparotid lymph node is extremely rare in non-immunocompromised human immuno-1 deficiency virus (HIV)-negative patients.
  • We report a case of a left parotid mass as an early sign of Kaposi's sarcoma-associated human herpesvirus 8 (HHV-8) infection in a 57-year-old patient.
  • After subtotal parotidectomy and histopathological diagnosis of lymph node localization of Kaposi's sarcoma, an accurate dermatological investigation revealed a solitary small lesion in the left foot.
  • Chemotherapy with five cycles of vincristine gave a temporary response of the cutaneous lesion.
  • Seven months later, a few small, firm, purplish-red lesions appeared in different areas of the body, but no adjuvant treatment was accepted by the patient since the lesions occasionally disappeared or remained stable in size.
  • The problems related to the diagnosis, the management strategy of such a rare condition and the prognosis are also discussed.
  • [MeSH-major] Herpesvirus 8, Human. Parotid Neoplasms / virology. Sarcoma, Kaposi / virology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12385365.001).
  • [ISSN] 0022-2151
  • [Journal-full-title] The Journal of laryngology and otology
  • [ISO-abbreviation] J Laryngol Otol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  •  go-up   go-down


16. Eiling S, Lischner S, Busch JO, Rothaupt D, Christophers E, Hauschild A: Complete remission of a radio-resistant cutaneous angiosarcoma of the scalp by systemic treatment with liposomal doxorubicin. Br J Dermatol; 2002 Jul;147(1):150-3
Hazardous Substances Data Bank. DOXORUBICIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Complete remission of a radio-resistant cutaneous angiosarcoma of the scalp by systemic treatment with liposomal doxorubicin.
  • Additionally, a cervical lymph node metastasis appeared for the first time.
  • Following six cycles, the patient clinically showed a complete remission of all skin lesions and the cervical lymph node; metastasis was confirmed by histology and fine needle aspiration, respectively.
  • Liposomal and pegylated doxorubicin, a cytostatic drug belonging to the anthracyclines, has already shown to be effective and mostly well tolerated in the therapy of acquired immune deficiency syndrome-related Kaposi's sarcoma and very recently in cutaneous T-cell lymphoma, too.
  • Caelyx(R) appears to be a promising alternative to conventional treatment of cutaneous angiosarcoma.
  • [MeSH-major] Antineoplastic Agents / administration & dosage. Doxorubicin / administration & dosage. Head and Neck Neoplasms / drug therapy. Hemangiosarcoma / drug therapy. Scalp. Skin Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12100199.001).
  • [ISSN] 0007-0963
  • [Journal-full-title] The British journal of dermatology
  • [ISO-abbreviation] Br. J. Dermatol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Liposomes; 80168379AG / Doxorubicin
  •  go-up   go-down


17. Yuan ZG, Dun XY, Li YH, Hou J: Treatment of multicentric Castleman's Disease accompanying multiple myeloma with bortezomib: a case report. J Hematol Oncol; 2009;2:19
Hazardous Substances Data Bank. BORTEZOMIB .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment of multicentric Castleman's Disease accompanying multiple myeloma with bortezomib: a case report.
  • Multicentric Castleman's disease (MCD) is a rare lymphoproliferative disorder of unknown etiology and characterized by various clinical manifestations and multiple organ involvement.
  • It has been reported in association with POEMS syndrome and can progress to Kaposi's sarcoma or malignant lymphoma.
  • Optimal therapies have not been well established up to now.
  • We here reported a case of rare MCD complicated with multiple myeloma who received bortezomib and achieved very good remission.
  • To our knowledge, this is the first report on MCD in the setting of multiple myeloma with good response to bortezomib.
  • [MeSH-major] Boronic Acids / therapeutic use. Giant Lymph Node Hyperplasia / complications. Giant Lymph Node Hyperplasia / drug therapy. Multiple Myeloma / complications. Multiple Myeloma / drug therapy. Neoplasms, Multiple Primary / drug therapy. Pyrazines / therapeutic use
  • [MeSH-minor] Aged. Antineoplastic Agents / therapeutic use. Bortezomib. Humans. Male. Remission Induction


18. Jacobs SA, Vidnovic N, Patel H, Soma LA, Chang Y, Bass N, Swerdlow SH: Durable remission of HIV-negative, Kaposi's sarcoma herpes virus-associated multicentric Castleman disease in patient with rheumatoid arthritis treated with methotrexate. Clin Rheumatol; 2007 Jul;26(7):1148-50
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Durable remission of HIV-negative, Kaposi's sarcoma herpes virus-associated multicentric Castleman disease in patient with rheumatoid arthritis treated with methotrexate.
  • Multicentric Castleman disease (MCD) is a nonneoplastic lymphoproliferative disorder that has a poor prognosis.
  • Optimal treatment is unknown.
  • In this study, we report a patient with rheumatoid arthritis diagnosed with Kaposi's sarcoma herpesvirus-(KSHV, human herpesvirus-8) associated MCD that showed expression of viral IL-6.
  • Treatment with methotrexate (MTX) resulted in a complete remission of her disease lasting for 54+ months.
  • Multiple studies have suggested that MCD and rheumatoid arthritis are associated with overexpression of the growth-promoting cytokine interleukin-6 (IL-6), and that MTX downregulates the production of this cytokine in vivo.
  • [MeSH-major] Arthritis, Rheumatoid / drug therapy. Giant Lymph Node Hyperplasia / drug therapy. Herpesvirus 8, Human / isolation & purification. Immunosuppressive Agents / therapeutic use. Methotrexate / therapeutic use. Sarcoma, Kaposi / drug therapy


19. Waterston A, Bower M: Fifty years of multicentric Castleman's disease. Acta Oncol; 2004;43(8):698-704
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • MCD is associated with Kaposi's sarcoma herpesvirus (KSHV) infection, which is alternatively termed human herpesvirus 8 (HHV8).
  • The diagnosis of Castleman's disease is established by biopsy and treatment is often based on published case reports only, as there are no randomized trials of therapy.
  • Systemic treatments for MCD have included chemotherapy, anti-herpesvirus treatments to reduce the KSHV viral load, highly active antiretroviral therapy (HAART) to reduce HIV viraemia and latterly monoclonal antibodies against both IL 6 and CD20.
  • Optimization and consensus in treatment of these patients remains a target for the future.
  • [MeSH-major] Giant Lymph Node Hyperplasia / diagnosis. Herpesvirus 8, Human / isolation & purification. Interleukin-6 / analysis. Sarcoma, Kaposi / diagnosis
  • [MeSH-minor] Aged. Animals. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Antiretroviral Therapy, Highly Active / methods. Combined Modality Therapy. Female. Humans. Immunohistochemistry. Male. Mice. Middle Aged. Prognosis. Risk Assessment. Severity of Illness Index. Viral Load


20. Wang YF, Hsieh YF, Lin CL, Lin JL, Chen CY, Chiou YH, Chou MC: Staurosporine-induced G2/M arrest in primary effusion lymphoma BCBL-1 cells. Ann Hematol; 2004 Dec;83(12):739-44
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Staurosporine, an inhibitor of protein kinase C, is a potential antitumor drug and its derivatives are used as anticancer drugs in clinical trials.
  • Human herpesvirus 8 (HHV-8) is implicated in all forms of Kaposi's sarcoma (KS), primary effusion lymphoma (PEL), and multicentric Castleman's disease (MCD), indicating it to be a DNA tumor virus.
  • Our results show that staurosporine treatment reduces the cell viability of BCBL-1 cells and causes cell cycle arrest in the G2/M phase.
  • Furthermore, the induction of the HHV-8 lytic cycle was not observed under the staurosporine treatment.
  • [MeSH-major] Cell Division / drug effects. Enzyme Inhibitors / pharmacology. G2 Phase / drug effects. Herpesvirus 8, Human. Lymphoma, B-Cell / drug therapy. Staurosporine / pharmacology
  • [MeSH-minor] CDC2 Protein Kinase / metabolism. Cell Line, Tumor. Cell Survival / drug effects. Cyclin B / metabolism. DNA Viruses / metabolism. Giant Lymph Node Hyperplasia / drug therapy. Giant Lymph Node Hyperplasia / pathology. Giant Lymph Node Hyperplasia / virology. Humans. Protein Kinase C / antagonists & inhibitors. Protein Kinase C / metabolism. Sarcoma, Kaposi / drug therapy. Sarcoma, Kaposi / pathology. Sarcoma, Kaposi / virology. Virus Replication / drug effects

  • Genetic Alliance. consumer health - Primary effusion lymphoma.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15452667.001).
  • [ISSN] 0939-5555
  • [Journal-full-title] Annals of hematology
  • [ISO-abbreviation] Ann. Hematol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Cyclin B; 0 / Enzyme Inhibitors; EC 2.7.11.13 / Protein Kinase C; EC 2.7.11.22 / CDC2 Protein Kinase; H88EPA0A3N / Staurosporine
  •  go-up   go-down


21. Newsom-Davis T, Bower M, Wildfire A, Thirlwell C, Nelson M, Gazzard B, Stebbing J: Resolution of AIDS-related Castleman's disease with anti-CD20 monoclonal antibodies is associated with declining IL-6 and TNF-alpha levels. Leuk Lymphoma; 2004 Sep;45(9):1939-41
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Primary therapy with single agent rituximab was associated with a near complete response.
  • During this time, his KSHV (Kaposi's sarcoma-associated herpesvirus) viral load decreased and we also observed immediate, large and sustained decreases in interleukin-6 (IL-6) and tumor necrosis factor-alpha levels (TNF-alpha).
  • [MeSH-major] Acquired Immunodeficiency Syndrome / complications. Antibodies, Monoclonal / therapeutic use. Antigens, CD20 / immunology. Giant Lymph Node Hyperplasia / complications. Giant Lymph Node Hyperplasia / drug therapy. Interleukin-6 / metabolism. Tumor Necrosis Factor-alpha / metabolism

  • Genetic Alliance. consumer health - Castleman's Disease.
  • Genetic Alliance. consumer health - AIDS-HIV.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • Hazardous Substances Data Bank. RITUXIMAB .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2004 Taylor and Francis Ltd
  • (PMID = 15223659.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Antigens, CD20; 0 / Interleukin-6; 0 / Tumor Necrosis Factor-alpha; 4F4X42SYQ6 / Rituximab
  •  go-up   go-down


22. Mylona EE, Baraboutis IG, Lekakis LJ, Georgiou O, Papastamopoulos V, Skoutelis A: Multicentric Castleman's disease in HIV infection: a systematic review of the literature. AIDS Rev; 2008 Jan-Mar;10(1):25-35
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The objective of this study is to systematically review the epidemiology and the clinical and virologic aspects of multicentric Castleman's disease in HIV-positive patients and to evaluate treatment strategies and outcome, especially in relation to HAART administration.
  • Of them, the majority (90%) were men with 33 months median time from detection of HIV-positivity to multicentric Castleman's disease diagnosis in the HAART era.
  • Kaposi's sarcoma was present in 72% of the patients and respiratory system involvement in 34%.
  • Of the 48 patients on HAART, 64% were already on HAART at multicentric Castleman's disease diagnosis, having a better immunologic profile and a lower incidence of Kaposi's sarcoma than the 35% of patients who initiated HAART after multicentric Castleman's disease diagnosis.
  • At multicentric Castleman's disease diagnosis, a wide range of CD4 counts was recorded, suggesting that disease presentation could occur at any CD4 count.
  • With regard to treatment, the study confirmed the high rates of response with rituximab (anti-CD20 monoclonal).
  • Other regimens used in the treatment of HIV-related multicentric Castleman's disease were antiviral agents, immunomodulatory agents, and thalidomide.
  • Infection, multiorgan failure, Kaposi's sarcoma, non-Hodgkin lymphoma and progressive multicentric Castleman's disease were the most often reported causes of death.
  • In conclusion, multicentric Castleman's disease is a lymphoproliferative disorder with an increasing prevalence in HIV-infected individuals.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Giant Lymph Node Hyperplasia / complications. HIV Infections / complications
  • [MeSH-minor] Antiretroviral Therapy, Highly Active / methods. Humans


23. Aoki Y, Tosato G: Therapeutic options for human herpesvirus-8/Kaposi's sarcoma-associated herpesvirus-related disorders. Expert Rev Anti Infect Ther; 2004 Apr;2(2):213-25
HIV InSite. treatment guidelines - Human Herpesvirus-8 .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Therapeutic options for human herpesvirus-8/Kaposi's sarcoma-associated herpesvirus-related disorders.
  • Human herpesvirus-8/Kaposi's sarcoma-associated herpesvirus infection is associated with three proliferative disorders in immunocompromised patients - Kaposi's sarcoma, primary effusion lymphoma and multicentric Castleman's disease.
  • These disorders often develop in patients with advanced AIDS who present a number of therapeutic challenges, underscoring the importance of continuing efforts dedicated to basic and clinical research in this field.
  • In the era of highly active antiretroviral therapy, the incidence of AIDS and Kaposi's sarcoma has considerably decreased, presumably due to enhanced anti-Kaposi's sarcoma-associated herpesvirus immune responses, whereas the situation with primary effusion lymphoma and multicentric Castleman's disease is more complex.
  • Based on advances in the understanding of Kaposi's sarcoma-associated herpesvirus-related disorders and availability of antiretroviral agents, current and future therapeutic approaches will be discussed.
  • [MeSH-major] Acquired Immunodeficiency Syndrome / drug therapy. Giant Lymph Node Hyperplasia / drug therapy. Herpesvirus 8, Human. Lymphoma, Non-Hodgkin / drug therapy. Sarcoma, Kaposi / drug therapy
  • [MeSH-minor] Antiretroviral Therapy, Highly Active. Humans

  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • MedlinePlus Health Information. consumer health - Kaposi's Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15482187.001).
  • [ISSN] 1478-7210
  • [Journal-full-title] Expert review of anti-infective therapy
  • [ISO-abbreviation] Expert Rev Anti Infect Ther
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 119
  •  go-up   go-down


24. Régnier-Rosencher E, Barrou B, Marcelin AG, Jacobzone-Leveque C, Cadranel J, Leblond V, Francès C: [Primary effusion lymphoma in two kidney transplant recipients]. Ann Dermatol Venereol; 2010 Apr;137(4):285-9
MedlinePlus Health Information. consumer health - Kidney Transplantation.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Transliterated title] Lymphome des séreuses chez le transplanté rénal: deux cas.
  • BACKGROUND: Primary effusion lymphoma (PEL) is a highly malignant non-Hodgkin lymphoma associated with Kaposi's sarcoma-associated herpesvirus/human herpesvirus-8 infection (KSHV/HHV-8).
  • OBSERVATION: We describe two male kidney transplant recipients, aged 47 and 51 years, followed for Kaposi's sarcoma in skin, lymph nodes, gastrointestinal (GI) tract and lung whose disease was poorly controlled by sirolimus and chemotherapy.
  • Recurrent pleural effusion contrasted with reduction of cutaneous Kaposi lesions.
  • CONCLUSION: The contrast between a very low KHSV viral load in plasma and a very high viral load pleural effusion should alert physicians and prompt suspicion of PEL in Kaposi's sarcoma patients with recurrent serous effusion.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / adverse effects. Epstein-Barr Virus Infections / etiology. Herpesvirus 4, Human / isolation & purification. Herpesvirus 8, Human / isolation & purification. Immunosuppressive Agents / adverse effects. Kidney Transplantation. Lymphoma, Primary Effusion / etiology. Neoplasms, Multiple Primary / etiology. Postoperative Complications / etiology
  • [MeSH-minor] Digestive System Neoplasms / drug therapy. Digestive System Neoplasms / secondary. Digestive System Neoplasms / virology. Fatal Outcome. Giant Lymph Node Hyperplasia / complications. Giant Lymph Node Hyperplasia / virology. Humans. Immunocompromised Host. Kidney Failure, Chronic / etiology. Kidney Failure, Chronic / surgery. Lung Neoplasms / drug therapy. Lung Neoplasms / secondary. Lung Neoplasms / virology. Lymphatic Metastasis. Male. Middle Aged. Pleural Effusion, Malignant / cytology. Pleural Effusion, Malignant / virology. Sarcoma, Kaposi / drug therapy. Sarcoma, Kaposi / etiology. Sarcoma, Kaposi / virology. Skin Neoplasms / drug therapy. Skin Neoplasms / etiology. Skin Neoplasms / virology. Viral Load

  • Genetic Alliance. consumer health - Primary effusion lymphoma.
  • MedlinePlus Health Information. consumer health - After Surgery.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2010 Elsevier Masson SAS. All rights reserved.
  • (PMID = 20417362.001).
  • [ISSN] 0151-9638
  • [Journal-full-title] Annales de dermatologie et de vénéréologie
  • [ISO-abbreviation] Ann Dermatol Venereol
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Immunosuppressive Agents
  •  go-up   go-down


25. Stebbing J, Pantanowitz L, Dayyani F, Sullivan RJ, Bower M, Dezube BJ: HIV-associated multicentric Castleman's disease. Am J Hematol; 2008 Jun;83(6):498-503
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Multicentric Castleman's disease (MCD), a relatively rare lymphoproliferative disorder that presents with heterogenous symptoms including fevers, anemia, and multifocal lymphadenopathy, is today most commonly observed in individuals infected with human immunodeficiency virus type-1 (HIV).
  • In such individuals, a lymph node biopsy typically identifies cells that stain for Kaposi's sarcoma-associated herpesvirus proteins, and most HIV-associated MCD features can be attributed to the presence of this gamma-herpesvirus.
  • Surgery and antiviral therapies including highly active antiretroviral therapy, interferon-alpha, foscarnet, ganciclovir, and antibodies to interleukin-6 have proved largely ineffective, and chemotherapy in HIV positive individuals is complicated by limited efficacy and pronounced toxicity.
  • While no randomized trials have been performed, more recently the use of the anti-CD20 monoclonal antibody rituximab in large single center cohorts has been associated with prolonged remissions, radiologic responses, as well as hematologic and serum chemistry normalization of the inflammatory picture observed, at the expense of B cell depletion and flare of Kaposi's sarcoma.
  • [MeSH-major] Giant Lymph Node Hyperplasia / virology. HIV Infections / complications


26. Scott D, Cabral L, Harrington WJ Jr: Treatment of HIV-associated multicentric Castleman's disease with oral etoposide. Am J Hematol; 2001 Feb;66(2):148-50
Hazardous Substances Data Bank. ETOPOSIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment of HIV-associated multicentric Castleman's disease with oral etoposide.
  • Multicentric Castleman's disease (MCD) is a lymphoproliferative disorder that can be defined based upon both clinical and pathological characteristics.
  • Human herpesvirus type 8 (HHV-8) DNA sequences have been detected in peripheral blood mononuclear cells (PBMCs) of patients with Kaposi's sarcoma and MCD, regardless of HIV infection status.
  • Treatment and outcomes in HIV associated MCD are generally unfavorable.
  • The first patient had relapsed on several occasions despite previous therapy with doxil, paclitaxel, and oral ganciclovir.
  • The second patient was treatment naive.
  • Both patients had HHV-8 detectable by polymerase chain reaction in PBMCs, widespread tumor, and B-type symptoms when therapy was initiated.
  • In both cases remissions (documented by computerized tomography) have been durable, 1.5 and 6 months, respectively, with minimal side effects.
  • [MeSH-major] Etoposide / administration & dosage. Giant Lymph Node Hyperplasia / drug therapy. HIV Infections / complications
  • [MeSH-minor] Administration, Oral. Adult. Anatomy, Cross-Sectional. Antineoplastic Agents, Phytogenic / administration & dosage. DNA, Viral / blood. Herpesvirus 8, Human / genetics. Humans. Male. Middle Aged. Tomography Scanners, X-Ray Computed


27. Boivin G, Côté S, Cloutier N, Abed Y, Maguigad M, Routy JP: Quantification of human herpesvirus 8 by real-time PCR in blood fractions of AIDS patients with Kaposi's sarcoma and multicentric Castleman's disease. J Med Virol; 2002 Nov;68(3):399-403
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Quantification of human herpesvirus 8 by real-time PCR in blood fractions of AIDS patients with Kaposi's sarcoma and multicentric Castleman's disease.
  • Our objective was to compare the HHV8 DNA load in serial blood samples (collected every 3 months for 1 year) from acquired immunodeficiency syndrome (AIDS) patients with Kaposi's sarcoma (KS) and multicentric Castleman's disease (MCD).
  • The HHV8 viral load was determined in both peripheral blood mononuclear cells (PBMC) and plasma fractions, using a competitive real-time polymerase chain reaction (PCR) assay developed in a LightCycler instrument (Roche Diagnostics).
  • In six subjects with limited or extensive KS while on highly active antiretroviral therapy, the HHV8 DNA load was either undetectable (<50 copies/10(5) cells) or low (</=135 copies) in all PBMC samples.
  • After chemotherapy, the HHV8 DNA load became undetectable in the MCD patients despite no changes in CD4 T-cell counts or highly active antiretroviral therapy (HAART) regimens.
  • [MeSH-major] AIDS-Related Opportunistic Infections / virology. DNA, Viral / blood. Giant Lymph Node Hyperplasia / virology. Herpesvirus 8, Human / isolation & purification. Sarcoma, Kaposi / virology. Viral Load


28. Heinzerling L, Dummer R, Wildberger H, Burg G: Cutaneous ulceration after injection of polyethylene-glycol-modified interferon alpha associated with visual disturbances in a melanoma patient. Dermatology; 2000;201(2):154-7
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Interferons are used in the therapy of multiple sclerosis, Kaposi's sarcoma, hepatitis and melanoma.
  • A 50-year-old patient was diagnosed as having an acrolentiginous melanoma (Breslow >5 mm, Clark level IV) and inguinal lymph node metastases.
  • After surgical excision and lymphadenectomy, immune therapy with 6.0 microg pegylated interferon alpha(2b)/kg body weight, s.c., was started.
  • Cutaneous ulcerations at the injection sites developed 9 months after treatment initiation.
  • The patient also developed blurred vision and presented with binasal scotomas and pathological visually evoked potentials and electroretinogram.
  • The cutaneous ulcerations slowly healed under local therapy and reduction of the concentration of the PEG-modified interferon from 0.86 to 0.43 mg/ml.
  • Two months later, the therapy was stopped due to disease progression.
  • [MeSH-major] Interferon-alpha / adverse effects. Melanoma / drug therapy. Polyethylene Glycols / adverse effects. Skin Ulcer / chemically induced. Vision Disorders / chemically induced

  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Vision Impairment and Blindness.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2000 S. Karger AG, Basel
  • (PMID = 11053921.001).
  • [ISSN] 1018-8665
  • [Journal-full-title] Dermatology (Basel, Switzerland)
  • [ISO-abbreviation] Dermatology (Basel)
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Interferon-alpha; 0 / Recombinant Proteins; 30IQX730WE / Polyethylene Glycols; 47RRR83SK7 / interferon alfa-2a; Q46947FE7K / peginterferon alfa-2a
  •  go-up   go-down


29. Lanzafame M, Carretta G, Trevenzoli M, Lazzarini L, Vento Ercole Concia S: Successful treatment of Castleman's disease with HAART in two HIV-infected patients. J Infect; 2000 Jan;40(1):90-1
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Successful treatment of Castleman's disease with HAART in two HIV-infected patients.
  • Recently, human herpesvirus type 8 (HHV-8) has been associated with various diseases in individuals with HIV infection, including Kaposi's sarcoma, B cell non Hodgkin's lymphomas, and Castleman's disease.
  • In Castleman's disease it has been hypothesized that HHV-8, encoding a number of various virokines, can be responsible for clinical manifestations of the disease.Previously, two reports have described a clinical recovery from HIV-associated Castleman's disease: by administration of a monoclonal antibody neutralizing human IL-6 in one case, and in another case by treatment with highly antiretroviral therapy and anti-herpesvirus therapy, following splenectomy.
  • [MeSH-major] Anti-HIV Agents / therapeutic use. Giant Lymph Node Hyperplasia / drug therapy. HIV Infections / complications. Reverse Transcriptase Inhibitors / therapeutic use
  • [MeSH-minor] Adult. Drug Therapy, Combination. Humans. Male. Treatment Outcome

  • Genetic Alliance. consumer health - Castleman's Disease.
  • Genetic Alliance. consumer health - HIV.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • MedlinePlus Health Information. consumer health - HIV/AIDS Medicines.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10762119.001).
  • [ISSN] 0163-4453
  • [Journal-full-title] The Journal of infection
  • [ISO-abbreviation] J. Infect.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] ENGLAND
  • [Chemical-registry-number] 0 / Anti-HIV Agents; 0 / Reverse Transcriptase Inhibitors
  •  go-up   go-down


30. Bertero MT, De Maestri M, Caligaris-Cappio F: Cyclophosphamide/cyclosporin-A treatment of multicentric Castleman's disease with Kaposi's sarcoma. Haematologica; 2000 Feb;85(2):216-7
Hazardous Substances Data Bank. CYCLOSPORIN A .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cyclophosphamide/cyclosporin-A treatment of multicentric Castleman's disease with Kaposi's sarcoma.
  • [MeSH-major] Cyclophosphamide / therapeutic use. Cyclosporine / therapeutic use. Giant Lymph Node Hyperplasia / complications. Giant Lymph Node Hyperplasia / drug therapy. Immunosuppressive Agents / therapeutic use. Sarcoma, Kaposi / complications. Sarcoma, Kaposi / drug therapy
  • [MeSH-minor] Drug Therapy, Combination. Female. Humans. Middle Aged


31. Law AB, Ryan G, Lade S, Prince HM: Development of Kaposi's sarcoma after complete remission of multicentric Castlemans disease with rituximab therapy in a HHV8-positive, HIV-negative patient. Int J Hematol; 2010 Mar;91(2):347-8; author reply 349
Hazardous Substances Data Bank. RITUXIMAB .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Development of Kaposi's sarcoma after complete remission of multicentric Castlemans disease with rituximab therapy in a HHV8-positive, HIV-negative patient.
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Antineoplastic Agents / therapeutic use. Giant Lymph Node Hyperplasia / drug therapy. Sarcoma, Kaposi / diagnosis. Sarcoma, Kaposi / virology

  • Genetic Alliance. consumer health - HIV.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Kaposi's Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentOn] Int J Hematol. 2009 Oct;90(3):392-6 [19756920.001]
  • [Cites] Ann Intern Med. 2007 Dec 18;147(12):836-9 [18087054.001]
  • [Cites] Actas Dermosifiliogr. 2006 Jul-Aug;97(6):385-90 [16956518.001]
  • [Cites] BMC Blood Disord. 2003 Dec 11;3(1):3 [14670091.001]
  • [Cites] Int J Hematol. 2009 Oct;90(3):392-6 [19756920.001]
  • [Cites] J Am Acad Dermatol. 2005 Jul;53(1):155-7 [15965441.001]
  • [Cites] Curr Opin Hematol. 2007 Jul;14 (4):354-9 [17534161.001]
  • [Cites] Blood. 1995 Aug 15;86(4):1276-80 [7632932.001]
  • [Cites] Int J Cancer. 2004 Jan 20;108(3):473-4 [14648716.001]
  • [Cites] Am J Surg Pathol. 2008 Jul;32(7):1006-12 [18469709.001]
  • [Cites] Blood. 2003 Oct 15;102(8):2786-8 [12842986.001]
  • [Cites] N Engl J Med. 2000 Apr 6;342(14):1027-38 [10749966.001]
  • [Cites] Curr Opin HIV AIDS. 2009 Jan;4(1):16-21 [19343828.001]
  • (PMID = 20146033.001).
  • [ISSN] 1865-3774
  • [Journal-full-title] International journal of hematology
  • [ISO-abbreviation] Int. J. Hematol.
  • [Language] eng
  • [Publication-type] Case Reports; Comment; Letter
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Antineoplastic Agents; 4F4X42SYQ6 / Rituximab
  •  go-up   go-down






Advertisement